Arrowstreet Capital
ADPT icon

Arrowstreet Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Arrowstreet Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.2M Buy
2,524,620
+529,418
+27% +$8.11M 0.02% 533
2026
Q1 		$27.7M Sell
1,995,202
-426,887
-18% -$6.8M 0.02% 660
2025
Q4 		$39.3M Sell
2,422,089
-19,313
-0.8% -$315K 0.02% 541
2025
Q3 		$36.5M Buy
2,441,402
+2,062,282
+544% +$25.1M 0.02% 550
2025
Q2 		$4.42M Buy
379,120
+333,379
+729% +$3.03M ﹤0.01% 1218
2025
Q1 		$340K Buy
+45,741
New +$352K ﹤0.01% 1664
2021
Q1 		– Sell
-160,810
Closed -$9.51M – 2205
2020
Q4 		$9.51M Buy
+160,810
New +$8.29M 0.01% 902
2020
Q2 		– Sell
-74,715
Closed -$2.08M – 2269
2020
Q1 		$2.08M Buy
+74,715
New +$2.08M 0.01% 1051

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital's ADPT Position: Q2 2026 in Review

Arrowstreet Capital increased its Adaptive Biotechnologies (ADPT) stake by 27% in Q2 2026, buying an estimated $8.11M and bringing the position to 2,524,620 shares worth $54.2M. The position accounts for 0.02% of the portfolio, ranked #533.

Arrowstreet Capital first reported a position in ADPT in Q1 2020 and has held it in 8 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Arrowstreet Capital held 2,524,620 shares of Adaptive Biotechnologies worth $54.2M as of Q2 2026.
  • Arrowstreet Capital bought 529,418 Adaptive Biotechnologies shares in Q2 2026, an estimated $8.11M.
  • Adaptive Biotechnologies made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #533 holding.
  • Arrowstreet Capital first reported a position in Adaptive Biotechnologies in Q1 2020 and has held it in 8 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.